U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H15N2O3.Na
Molecular Weight 234.2275
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BUTETHAL SODIUM

SMILES

[Na+].CCCCC1(CC)C(=O)NC([O-])=NC1=O

InChI

InChIKey=QTNNCMYRNIXYPH-UHFFFAOYSA-M
InChI=1S/C10H16N2O3.Na/c1-3-5-6-10(4-2)7(13)11-9(15)12-8(10)14;/h3-6H2,1-2H3,(H2,11,12,13,14,15);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula C10H16N2O3
Molecular Weight 212.2456
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: http://www.doctoralia.co.uk/medication/soneryl-10028 | http://www.minclinic.ru/drugs/drugs_eng/S/Soneryl.html

Butethal is a sedative and a hypnotic drug indicated for the treatment of severe intractable insomnia. It acts on receptors in the brain (GABA A receptors) causing the release of the chemical GABA. This chemical inhibits certain areas of the brain resulting in sleepiness. Common side effects are: drowsiness, sedation, unsteadiness, vertigo and inco- ordination. Also, hangover effect, paradoxical excitement, confusion, memory defects and skin rashes. Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Soneryl

Approved Use

Soneryl is indicated for the treatment of insomnia.
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
37.5 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BUTETHAL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
The history of barbiturates a century after their clinical introduction.
2005 Dec
5-Butyl-5-ethylbarbituric acid: a phase transition at low temperature.
2005 May
40 years hard labour.
2008 May
Patents

Sample Use Guides

In Vivo Use Guide
100-200 mg at bedtime
Route of Administration: Oral
In Vitro Use Guide
Butethal enhanced GABA binding to rat brain synaptosomal membranes in a dose-dependent manner with the threshold concentration at 6.25 uM.
Substance Class Chemical
Created
by admin
on Sat Dec 16 08:39:04 GMT 2023
Edited
by admin
on Sat Dec 16 08:39:04 GMT 2023
Record UNII
12BJQ6C34C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BUTETHAL SODIUM
Common Name English
BUTOBARBITAL SODIUM
Systematic Name English
SODIUM 5-ETHYL-5-BUTYLBARBITURATE
Systematic Name English
BUTOBARBITONE SODIUM
Systematic Name English
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-BUTYL-5-ETHYL-, SODIUM SALT (1:1)
Systematic Name English
2,4,6(1H,3H,5H)-PYRIMIDINETRIONE, 5-BUTYL-5-ETHYL-, MONOSODIUM SALT
Systematic Name English
Classification Tree Code System Code
DEA NO. 2100
Created by admin on Sat Dec 16 08:39:04 GMT 2023 , Edited by admin on Sat Dec 16 08:39:04 GMT 2023
Code System Code Type Description
CAS
35763-44-1
Created by admin on Sat Dec 16 08:39:04 GMT 2023 , Edited by admin on Sat Dec 16 08:39:04 GMT 2023
PRIMARY
FDA UNII
12BJQ6C34C
Created by admin on Sat Dec 16 08:39:04 GMT 2023 , Edited by admin on Sat Dec 16 08:39:04 GMT 2023
PRIMARY
ECHA (EC/EINECS)
252-713-3
Created by admin on Sat Dec 16 08:39:04 GMT 2023 , Edited by admin on Sat Dec 16 08:39:04 GMT 2023
PRIMARY
EPA CompTox
DTXSID30957159
Created by admin on Sat Dec 16 08:39:04 GMT 2023 , Edited by admin on Sat Dec 16 08:39:04 GMT 2023
PRIMARY
PUBCHEM
23681182
Created by admin on Sat Dec 16 08:39:04 GMT 2023 , Edited by admin on Sat Dec 16 08:39:04 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY